Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data -Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression LONDON, March 07, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted…

Source